Innate Pharma S.A. (EPA:IPH)
France · Delayed Price · Currency is EUR 1.316
-0.034 (-2.52%)
Oct 2, 2026, 5:35 PM CET
Innate Pharma Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Strong Buy" and an average price target of €5.90. The average 1-year stock price forecast is 348.33% higher than the current stock price, while the lowest is €5.60 (+325.53%) and the highest is €6.20 (+371.12%).
Price Target: €5.90 (+348.33%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Innate Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Jun '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 2 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
44.17M
from 9.01M
Increased by 390.56%
Revenue Next Year
107.37M
from 44.17M
Increased by 143.06%
EPS This Year
0.95
EPS Next Year
2.15
from 0.95
Increased by 126.32%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.